Video

Dr. Goldstein on Fulvestrant in Metastatic Breast Cancer

Dr. Lori Goldstein from Fox Chase Cancer Center on Fulvestrant in Metastatic Breast Cancer

Lori J. Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, co-leader, Breast Cancer Clinical Research Program, Fox Chase Cancer Center, discusses the role of fulvestrant (Faslodex) in the metastatic breast cancer setting.

Fulvestrant is a selective estrogen receptor down-regulator (SERD) that is equivalent to aromatase inhibitors in the second-line setting and anastrozole (Arimidex) in the first-line setting.

The Phase III CONFIRM trial compared fulvestrant at doses of 250 mg and 500 mg in order to discover the best dosing schedule. The result of the trial is a 500 mg dose administered on days 1, 14 and 28, followed by 500 mg every 28 days.

Long-term trials suggest that fulvestrant offers a superior time to progression over anastrozole in the first-line setting. The trial investigating this idea is still in early phases but does supply further choices for patients with metastatic estrogen receptor positive breast cancer.

Related Videos
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD
Marc-Oliver Grimm, MD
Chun Chao, PhD, MS
Mikkael A. Sekeres, MD
Noa Biran, MD
Ranee Mehra, MD, professor, medicine, medical oncology; director, Head and Neck Medical Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical System